Learn how to choose the right investments for your financial goals and risk tolerance, with insights from expert Brian Feroldi.

Shares more than doubled after the gene therapy company announced that it has accepted a buyout offer. Here are the key details.

Shares slump after the company reports weak third-quarter results and cuts guidance. Here's what investors need to know.

The company top-selling eye disease drug continues to grow rapidly, but an increase in spending caused profits to wane. Shares bounced back from a rough start to the year after management made the ...

The market for project management solutions has grown explosively in the last decade, and Asana is well-positioned to capture a healthy piece of that opportunity.

A CVS/Aetna mega-merger could be a game-changer for the American healthcare system. Too bad Wall Street doesn't think that it is going to happen.

First-quarter results came in ahead of management's revised guidance, but the company warns that the operating environment still remains challenging.

Overall sales growth remains muted, but recent corporate tax cuts enabled the company to crank out double-digit profit growth.

The markets may loathe Nordstrom, CVS Health, and Chipotle right now, but our team of Fools thinks all three are compelling buys.

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

The niche software provider has rolled out several new services that could help it continue to win its fair share of new business.